Several categories of medication can increase sexual desire as a side effect, sometimes dramatically. The most well-documented culprits are dopamine-boosting drugs used for Parkinson’s disease, but stimulants, certain antidepressants, and even FDA-approved libido treatments work through similar brain chemistry. Here’s what’s known about each one and why these effects happen.
Why Some Medications Increase Sex Drive
The common thread linking most of these drugs is dopamine, a brain chemical tied to reward, motivation, and wanting. When a medication floods dopamine pathways, it doesn’t just treat the condition it was prescribed for. It can also amplify the brain’s “wanting” signal for pleasurable experiences, including sex. This creates what researchers call incentive salience: your brain assigns an unusually high priority to pursuing a reward, sometimes higher than the actual satisfaction you get from it. The result is a persistent, sometimes overwhelming urge.
Dopamine also appears to interfere with the brain circuits responsible for impulse control, the ones that normally help you dial back a desire once you’ve registered it. So the effect is two-fold: stronger urges and a weakened ability to resist them.
Parkinson’s Disease Medications
Dopamine agonists prescribed for Parkinson’s disease are the most studied medications linked to compulsive sexual behavior. Drugs like pramipexole and ropinirole directly stimulate dopamine receptors to help with movement problems, but they also activate reward pathways in ways that can trigger hypersexuality, compulsive gambling, binge eating, and uncontrolled spending.
The numbers are striking. In a longitudinal study published in Neurology, about 8.5% of Parkinson’s patients had compulsive sexual behaviors at baseline. Over five years, the overall rate of impulse control disorders (which includes hypersexuality along with other compulsive behaviors) climbed from roughly 20% to 33%. Among patients who had ever used dopamine agonists, the five-year cumulative incidence of developing at least one impulse control disorder reached 51.5%, compared to just 12.4% in those who never took them.
FDA-approved labeling for pramipexole specifically warns that patients “can experience intense urges to gamble, increased sexual urges, intense urges to spend money uncontrollably, binge eating, and/or other intense urges” while on dopamine-boosting medications. The labeling also notes that patients often don’t recognize these behaviors as abnormal, which is why prescribers are advised to ask about them directly.
Stimulants for ADHD
Amphetamine-based stimulants like those used to treat ADHD list changes in libido among their possible side effects. These medications increase dopamine and norepinephrine levels in the brain, which can shift sexual desire in either direction.
Research on amphetamine use (primarily studied in the context of illicit use) found that among 1,159 males, half reported the drugs had affected their sex life. Some experienced increased sexual desire, while others found it decreased. Many reported more intense orgasms but reduced overall sexual satisfaction. The effect appears to vary significantly from person to person, and the direction of the change isn’t predictable. Males seem to be more commonly affected based on available data, though research in other populations is limited.
Bupropion
Bupropion stands out among antidepressants because it works on dopamine and norepinephrine rather than serotonin. Most traditional antidepressants (SSRIs) are notorious for killing libido, but bupropion tends to do the opposite. In a placebo-controlled trial published in The Journal of Clinical Psychiatry, patients taking bupropion experienced significantly greater improvement in sexual desire and frequency of sexual activity compared to placebo by week four. The study specifically tested bupropion as an antidote to SSRI-induced sexual dysfunction, and it worked: patients reported wanting sex more and actually having it more often.
This is why bupropion is sometimes prescribed alongside an SSRI, or chosen instead of one, when sexual side effects are a concern. It’s not typically described as causing hypersexuality in the way Parkinson’s drugs can, but the boost in desire is real and measurable.
FDA-Approved Medications for Low Desire
Two medications are specifically designed to increase sexual desire in women with hypoactive sexual desire disorder (HSDD). Bremelanotide, sold as Vyleesi, works on melanocortin receptors in the brain rather than dopamine pathways. It’s administered as an injection before sexual activity, and clinical studies showed improvements in desire, arousal, and orgasm scores at a 1.75 mg dose compared to placebo.
Flibanserin, sold as Addyi, takes a different approach by adjusting serotonin and dopamine balance. It’s a daily pill rather than an as-needed treatment. Both medications are approved only for premenopausal women, and the effects tend to be modest compared to the dramatic changes seen with dopamine agonists.
Trazodone and Physical Arousal
Trazodone, an antidepressant commonly prescribed as a sleep aid, deserves a mention with an important distinction. It’s not well-documented as a driver of increased desire, but it’s one of the medications most frequently associated with priapism: a prolonged, painful erection lasting more than four hours that occurs without sexual stimulation. Trazodone may be involved in nearly 80% of all cases of drug-induced priapism, though the overall incidence is low, estimated between 1 in 1,000 and 1 in 10,000 users.
This is a physical arousal response, not a psychological increase in desire. The distinction matters because priapism is a medical emergency that can cause permanent damage if untreated.
What to Do if a Medication Changes Your Sex Drive
If you notice a significant shift in sexual desire after starting a new medication, the first step is recognizing that it’s likely a drug effect and not a personal failing or something to feel embarrassed about. This is especially important with dopamine agonists, where patients often don’t connect their behavior changes to the medication.
The standard clinical approach involves evaluating whether the dose can be lowered or whether switching to a different medication makes sense. With Parkinson’s drugs, for example, dopamine agonists carry a much higher risk of sexual compulsivity than levodopa, so a medication switch can sometimes resolve the problem. The goal is always to find the balance between treating the original condition and minimizing disruptive side effects.
For people whose increased desire is distressing or leading to risky behavior, bringing it up with a prescriber is essential. Compulsive sexual behavior linked to medication can escalate and carry real social, psychological, and legal consequences if left unaddressed.